Nisa Investment Advisors
THRX

Nisa Investment Advisors’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Nisa Investment Advisors’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,660
Closed -$15K – 2894
2023
Q1 		$15K Buy
+1,660
New +$16.3K ﹤0.01% 2086

Other funds holding THRX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Nisa Investment Advisors's THRX Position: Q2 2023 in Review

Nisa Investment Advisors sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q2 2023, closing a stake of 1,660 shares — an estimated $15K sold.

Nisa Investment Advisors first reported a position in THRX in Q1 2023 and held it in 1 quarter. The position peaked at $15K in Q1 2023. 69 funds tracked by Wall St. Rank hold THRX as of Q2 2023.

  • Nisa Investment Advisors reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Nisa Investment Advisors sold 1,660 Theseus Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $15K.
  • Nisa Investment Advisors first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Nisa Investment Advisors's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $15K in Q1 2023.
  • 69 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Nisa Investment Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.